Gapping up
In reaction to strong earnings/guidance:
- GRPN +4.7%, TPX +3.1% (Q2 guidance)
Other news:
- WATT +86.4% (announces partnership with Chinese battery manufacturer Grepow Battery)
- FLGT +19.7% (receives EUA from FDA to provide at-home testing services for SARS-CoV-2)
- HOOK +12.1% (announces FDA clearance for IND application for HB-202)
- CFRX +7.5% (announces publication of the exebacase Phase 2 study results in the July 1, 2020 issue of the Journal of Clinical Investigation)
- ARI +6.4% (lowers dividend)
- PTCT +5% (announces the initiation of a Phase 2/3 clinical trial to evaluate PTC299 for the treatment of COVID-19)
- AMRN +4.5% (announces settlement with Apotex)
- YUMC +4.5% (in discussions with banks over secondary Hong Kong listing, according to FT)
- NVS +2.6% (receives FDA approval for new indication for Cosentyx)
- CHGG +2.4% (authorizes repurchase of $500 mln of stock and/or convertible notes)
- ORC +2.4% (indicated higher after declaring unchanged June 2020 monthly dividend of $0.055 per share of common stock)
- SWAV +2% (prices offering of 1,700,000 shares of its common stock at $45.75 per share)
Analyst comments:
- NKLA +4.8% (initiated with an Outperform at Cowen)
- WPP +2.5% (upgraded to Buy from Neutral at Goldman)
- AMZN +0.9% (initiated with a Buy at Needham; tgt $3200)